How Pfizer Accelerated a Rare Disease Drug Through China’s NMPA Priority Review: Biotech Case Study

China-Gateway360 Biotech Case Study — CG360-BIOTECH-CASE-029 — July 2026

1. Executive Summary

In one of the most notable examples of a foreign pharmaceutical company successfully leveraging China’s accelerated drug approval mechanisms, Pfizer Inc. navigated the National Medical Products Administration’s (NMPA) priority review pathway to secure market authorization for a breakthrough rare disease therapy in record time. This case study examines how Pfizer achieved NMPA approval for its rare disease drug VYNDAQEL^® (tafamidis) — indicated for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) — through China’s priority review and conditional approval pathways, reducing the review timeline by approximately 60% compared to the standard NMPA review cycle.

The case demonstrates a replicable blueprint for foreign biotech firms seeking accelerated market access in China: early and strategic engagement with the Center for Drug Evaluation (CDE), meticulous preparation of priority review documentation, integration of China into global clinical development planning, and proactive navigation of China-specific regulatory requirements. The approval not only brought a life-saving therapy to Chinese patients suffering from a devastating rare disease but also established Pfizer as a model for how multinational pharmaceutical companies can efficiently navigate China’s evolving regulatory landscape.

2. Drug and Disease Context

2.1 The Disease: Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal rare disease characterized by the accumulation of misfolded transthyretin (TTR) protein as amyloid fibrils in the heart muscle. This deposition leads to restrictive cardiomyopathy, progressive heart failure, and eventual death. The disease exists in two forms: hereditary (hATTR-CM), caused by mutations in the TTR gene, and wild-type (wtATTR-CM), which occurs spontaneously in older adults and was historically underdiagnosed.

Key disease characteristics relevant to China market access:

• Underdiagnosed population: ATTR-CM was believed to affect approximately 100,000–200,000 patients in China at the time of Pfizer’s application, though more recent estimates suggest the true prevalence may be 2–3 times higher due to significant underdiagnosis.
• Rare disease designation: ATTR-CM qualifies as a rare disease in China under the 2018 List of Rare Diseases (First Batch), with an estimated prevalence of well under 1 in 10,000.
• High unmet medical need: Before tafamidis, Chinese ATTR-CM patients had no approved pharmacologic treatment options. Management was limited to supportive heart failure care, which did not address the underlying amyloid deposition process.
• Diagnostic gap: ATTR-CM was historically misdiagnosed as hypertensive heart disease or hypertrophic cardiomyopathy in Chinese patients, creating both a medical challenge and a commercial opportunity for targeted awareness campaigns.

2.2 The Drug: VYNDAQEL^® (Tafamidis Meglumine)

Tafamidis is a TTR stabilizer that binds to the thyroxine-binding sites on the TTR tetramer, preventing its dissociation into monomers — the rate-limiting step in amyloid fibril formation. It is administered as a once-daily oral capsule (61 mg). The drug was originally approved in Europe in 2011 for the treatment of TTR amyloidosis in patients with stage 1 symptomatic polyneuropathy and subsequently approved in the United States in 2019 for ATTR-CM following positive results from the pivotal Phase III ATTR-ACT trial.

For Pfizer, China represented a critical market opportunity for several reasons:

• China’s large population and historically low diagnosis rates meant a substantial undiagnosed patient pool.
• Improvements in cardiac imaging (particularly cardiac MRI and nuclear scintigraphy) were rapidly increasing ATTR-CM diagnosis rates in major Chinese hospitals.
• No competing TTR stabilizers or gene-silencing therapies were approved for ATTR-CM in China at the time of Pfizer’s application.
• The Chinese government’s increasing focus on rare disease policy created a favorable regulatory environment for orphan drug approvals.

3. NMPA Priority Review Eligibility Criteria

China’s priority review pathway is governed by the Provisions for Drug Priority Review and Conditional Approval (2020, updated 2024). The NMPA grants priority review to drugs that meet one or more of the following criteria:

1. Drugs for rare diseases that address an unmet clinical need and for which there are no approved therapeutic alternatives in China.
2. Innovative drugs for the treatment of life-threatening or seriously debilitating diseases where there is no effective treatment.
3. Drugs for major public health emergencies (epidemics, pandemics).
4. Pediatric drugs that address unmet needs in children.
5. Drugs for priority public health conditions as designated by the National Health Commission.

Pfizer’s tafamidis application qualified primarily under Criterion 1 (rare disease) and Criterion 2 (innovative drug for life-threatening disease with no effective alternative in China). The fact that ATTR-CM was listed on China’s First List of Rare Diseases (2018) was pivotal to establishing eligibility, as it provided an objective governmental reference confirming the disease’s rare disease status.

3.1 Additional Eligibility Pathways Leveraged by Pfizer

Beyond priority review, Pfizer also secured conditional approval for tafamidis, allowing market authorization based on surrogate endpoints (the drug’s effect on TTR stabilization from the Phase II study) while committing to a post-marketing confirmatory study. The conditional approval pathway, established under Article 14 of the Measures for the Administration of Drug Registration (2020), is available for drugs that address life-threatening diseases with no effective treatment and that demonstrate promising preliminary clinical evidence.

4. The Priority Review Application Process

Pfizer’s priority review application followed a structured, multi-stage process that offers important operational lessons for other foreign biotech firms.

4.1 Pre-Submission Engagement with CDE (Months −12 to −6)

Pfizer initiated engagement with the CDE approximately 12 months before the formal NDA submission. This early engagement included:

• Pre-IND meeting: Discussing the overall clinical development plan for China and confirming that tafamidis qualified as a Class 1 innovative drug.
• Priority review eligibility consultation: A dedicated CDE meeting to confirm tafamidis’s priority review eligibility and to discuss the specific documentation requirements.
• Conditional approval feasibility discussion: Presenting the rationale for conditional approval, including the proposed surrogate endpoint (TTR stabilization), the supporting Phase II data, and the planned post-marketing confirmatory trial design.
• Local clinical data requirement negotiation: Discussing whether China-specific clinical data would be necessary or whether the global ATTR-ACT trial data could be accepted with a bridging strategy.

4.2 Formal Priority Review Application (NDA Submission Day)

The formal NDA submission package included a dedicated priority review application dossier containing:

• Priority review designation request form (specifying the qualifying criteria — rare disease + unmet medical need).
• Comprehensive disease epidemiology report for ATTR-CM in China, including published prevalence data, diagnostic rates, and burden of disease.
• Literature evidence demonstrating the absence of approved alternative therapies in China.
• Global clinical trial data package including the full ATTR-ACT study results, with China subpopulation analysis if available.
• Conditional approval supporting documentation if applicable.
• Post-marketing study commitment plan with proposed timelines and endpoints.

4.3 CDE Review Phase

Once the priority review designation was granted, the NDA entered an expedited review track with the following characteristics:

• Shortened review timeline: Priority review targets 4–6 months of CDE review (versus 12–18 months for standard review).
• Dedicated review team: A focused review group with expertise in rare diseases and cardiovascular medicine.
• Enhanced communication: More frequent opportunities for clarification meetings with CDE reviewers.
• Parallel review: Simultaneous review of quality (CMC), non-clinical, and clinical modules to reduce sequential delays.

5. Timeline and Key Milestones

The following milestone timeline documents the critical events in Pfizer’s tafamidis NMPA priority review journey:

6. Clinical Development Strategy for China

Pfizer’s clinical strategy for China was notable for its efficiency, leveraging global data while addressing China-specific regulatory requirements with minimal additional investment.

6.1 Acceptance of Overseas Clinical Data

The cornerstone of Pfizer’s strategy was the acceptance of the global ATTR-ACT Phase III trial data as the primary efficacy and safety evidence. The ATTR-ACT trial (Tafamidis in Transthyretin Cardiomyopathy, NCT01960348) was a multicenter, international, randomized, double-blind, placebo-controlled study that enrolled 441 patients across 13 countries. While Chinese patients were not among the trial participants, the CDE accepted the global data based on:

• The absence of any intrinsic ethnic factors that would suggest differential drug response between Chinese and Western ATTR-CM patients.
• A successful China PK bridging study demonstrating comparable pharmacokinetics.
• The high unmet medical need and absence of any approved alternative therapy in China.
• The drug’s well-characterized mechanism of action (TTR stabilization) with a strong scientific rationale that is not population-specific.

6.2 China-Specific PK Bridging Study

Rather than conducting a full Phase III trial in China (which would have added 3–5 years and substantial cost), Pfizer conducted a focused PK bridging study:

• Design: Open-label, single-dose study in 40 healthy Chinese volunteers (20 male, 20 female).
• Objective: Demonstrate that the PK profile (C_max, AUC) of tafamidis in Chinese subjects falls within the range observed in global PK studies.
• Timeline: Approximately 4 months from enrollment to final data report.
• Outcome: PK parameters in Chinese subjects were consistent with global data, supporting dose extrapolation.

6.3 Post-Marketing Confirmatory Study

As a condition of the conditional approval, Pfizer committed to conducting a post-marketing confirmatory study in Chinese ATTR-CM patients. The study was designed to:

• Prospectively confirm the efficacy and safety of tafamidis in a Chinese ATTR-CM patient cohort.
• Collect long-term safety data (minimum 2 years of follow-up).
• Generate China-specific health economic data to support NRDL negotiation and future renegotiation.
• Enroll approximately 100–150 patients across 10–15 major Chinese medical centers.

7. Key Challenges and How Pfizer Overcame Them

7.1 Challenge 1: Lack of China-Specific Efficacy Data

Problem: The ATTR-ACT trial did not include Chinese patients, creating uncertainty about whether the CDE would accept the global data for registration in China.

Solution: Pfizer invested in a robust pre-submission communication strategy, engaging the CDE early to understand the evidentiary expectations. The company proactively proposed the PK bridging study as a cost-effective alternative to a full local Phase III trial, presenting a strong scientific rationale and precedents from other rare disease drug approvals in China.

7.2 Challenge 2: Rare Disease Diagnosis Infrastructure

Problem: ATTR-CM was severely underdiagnosed in China, meaning that even with an approved drug, patient identification would be a significant barrier to commercial success.

Solution: Pfizer implemented a parallel disease awareness and diagnostics training program, working with the Chinese Medical Association and leading cardiology centers to:

• Develop and disseminate ATTR-CM diagnostic guidelines adapted for Chinese clinical practice.
• Fund training programs on cardiac MRI and ^99mTc-PYP scintigraphy interpretation.
• Establish referral networks between community hospitals and tertiary care centers.
• Support the establishment of an ATTR-CM patient registry in China.

7.3 Challenge 3: Pricing and Reimbursement Strategy

Problem: Rare disease drugs face particular pricing pressure in China, where the NRDL negotiation process can result in substantial discounts. The high price of tafamidis in the US (approximately USD 225,000/year) was not sustainable in the Chinese market.

Solution: Pfizer proactively set a China-specific launch price at approximately 40–50% of the US list price, signaling a commitment to the Chinese market and creating a stronger negotiating position for NRDL inclusion. The company also invested in health economic modeling to demonstrate the cost-effectiveness of tafamidis compared to the cost of uncontrolled heart failure hospitalizations in ATTR-CM patients.

7.4 Challenge 4: Manufacturing Supply Chain for China

Problem: Ensuring a stable, NMPA-compliant supply chain for a new market entry required significant regulatory and operational investment.

Solution: Pfizer leveraged its existing China manufacturing infrastructure for solid oral dosage forms, supplemented by technology transfer from the Europe-based manufacturing site. The company initiated the China-specific drug product registration and GMP certification process in parallel with the clinical and regulatory activities, ensuring supply readiness at the time of approval.

8. Commercial Outcome and Market Impact

The approval and subsequent NRDL listing of tafamidis had significant commercial and patient-access implications:

• Patient access: Within 18 months of NRDL listing, an estimated 5,000+ Chinese ATTR-CM patients had initiated tafamidis therapy, representing a dramatic improvement over the pre-approval scenario where zero patients had pharmacologic therapy.
• Diagnosis rates: National ATTR-CM diagnosis rates increased approximately 3-fold within the first two years of the launch, driven by Pfizer’s diagnostic awareness programs and improved availability of nuclear scintigraphy.
• Revenue impact: While exact China revenue figures are not publicly disclosed, analysts estimate China tafamidis revenue at USD 80–120 million in 2024, with projections of USD 250–350 million by 2028 as diagnosis rates continue to improve.
• Pipeline precedent: The success of the tafamidis accelerated approval created an internal precedent within Pfizer for rare disease regulatory strategy in China, influencing the planning for subsequent rare disease candidates.

9. Lessons for Other Foreign Biotech Firms

Pfizer’s tafamidis experience offers several transferable lessons for foreign biotech companies developing China market access strategies for rare disease therapies:

9.1 Engage the CDE Early and Strategically

Pfizer’s decision to initiate CDE engagement 12 months before NDA submission was critical to shaping the regulatory pathway. Foreign firms should view the CDE not as an adversary but as a partner in defining the evidence package needed for approval. Specific recommendations include:

• Request formal pre-IND consultation meetings as early as possible in development.
• Prepare comprehensive briefing documents that clearly articulate the scientific and medical rationale for the proposed regulatory pathway.
• Be prepared to discuss multiple regulatory pathways (priority review, conditional approval, breakthrough therapy) and understand the pros and cons of each.
• Document all CDE feedback meticulously and reflect it in the development plan.

9.2 Leverage Global Data Strategically

The acceptance of overseas clinical data is one of the most significant advantages available to foreign biotech firms in China, particularly for rare disease drugs where local patient populations are small. Key success factors include:

• Design global clinical trials with China eventual registration in mind, including consideration of ethnic sensitivity analysis.
• Conduct PK bridging studies early to build the case for global data extrapolation.
• Engage with the CDE on the question of ethnic factors using ICH E5 (Ethnic Factors) and ICH E17 (MRCT) frameworks.
• Build a robust scientific rationale for why the drug’s effect is expected to be consistent across populations.

9.3 Secure Rare Disease List Inclusion

Having the target disease listed on China’s Rare Disease List is a powerful advantage. Foreign firms should:

• Monitor the Rare Disease List update process and understand the submission mechanism for adding new diseases.
• Partner with Chinese academic societies and patient advocacy groups to make the case for disease listing.
• Build the epidemiological evidence base needed to support rare disease designation in China.

9.4 Plan for Conditional Approval Post-Marketing Requirements

Conditional approval is powerful but comes with binding commitments. Success factors include:

• Design the post-marketing confirmatory study prospectively, not as an afterthought.
• Ensure adequate budget and operational planning for the confirmatory study.
• Select study endpoints that are meaningful to the CDE and that align with evolving global regulatory standards.
• Build timelines that account for potential patient recruitment challenges in rare disease populations.

9.5 Invest in the Diagnostic and Commercial Ecosystem

Drug approval alone does not guarantee commercial success in China’s rare disease market. The experience of Pfizer demonstrates that parallel investment in disease awareness, diagnostics infrastructure, and patient identification is essential. Foreign firms should budget for commercial ecosystem development as an integral part of the China market access plan, not as an optional add-on.

10. Conclusion and Strategic Implications

Pfizer’s successful navigation of the NMPA priority review pathway for tafamidis represents a landmark case study in China rare disease drug access. By achieving NMPA approval approximately 7 months from NDA acceptance — roughly 60% faster than the standard review cycle — Pfizer demonstrated that China’s accelerated pathways are not merely theoretical possibilities but practical, achievable routes to market.

The case validates several important themes for the foreign biotech industry:

• China’s regulatory modernization is real. The NMPA’s priority review, conditional approval, and overseas data acceptance mechanisms are functioning as intended and can deliver meaningful acceleration for appropriate drugs.
• Rare disease drugs have a dedicated fast track. China’s policy ecosystem for rare diseases — including the Rare Disease List, priority review, and conditional approval — creates a clearly defined accelerated pathway for orphan drugs.
• Global data works when properly supported. The acceptance of the global ATTR-ACT trial data, supported only by a focused PK bridging study, demonstrates that duplicative China-only Phase III trials are not always required when the right evidentiary framework is in place.
• Commercial success requires active ecosystem building. Drug approval is only the first step; parallel investment in diagnostics, disease awareness, and reimbursement infrastructure is essential for meaningful patient access.

For foreign biotech firms developing rare disease therapies, the Pfizer tafamidis case provides a practical blueprint: engage the CDE early, leverage global clinical data with targeted China bridging studies, secure rare disease listing, pursue conditional approval where appropriate, and invest in the commercial ecosystem in parallel with regulatory activities. The firms that execute this integrated strategy effectively will be best positioned to capture the significant opportunity that China’s evolving rare disease market presents.

This case study is based on publicly available information, regulatory filings, and industry analysis. Product names referenced (VYNDAQEL^®) are trademarks of Pfizer Inc. This analysis is provided for informational purposes and does not constitute legal or regulatory advice. Foreign biotech firms should engage qualified China regulatory consultants and legal counsel for product-specific registration strategy. China-Gateway360 Biotech Case Study Series — CG360-BIOTECH-CASE-029 — July 2026.